Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2024-10-27 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Share Purchase Plan Offer Booklet 19 pages 701.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Share Purchase Plan Booklet' and is dated 28 October 2024. It details an offer to existing shareholders to purchase additional shares at a discounted price, including terms and conditions, eligibility criteria, and payment instructions. It references a recent institutional placement and provides a timetable for the offer and allotment of shares. The document is a detailed booklet explaining the share purchase plan, which is a capital raising activity. It is not a financial report, earnings release, or regulatory filing. It is not a proxy statement or voting results announcement. The content focuses on the capital raising through a share purchase plan, which fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the actual offer document, not just an announcement or summary.
2024-10-27 English
Percheron launches post-trial access program 2 pages 112.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Percheron Therapeutics Limited providing an update on a post-trial access program for patients completing a Phase IIb clinical trial. It discusses the trial design, regulatory considerations, and next steps, but does not contain any financial data, earnings, or detailed report content. The document is relatively short (4503 characters) and serves as a corporate announcement about clinical trial progress and patient access rather than a financial or regulatory filing. It is not an Annual Report, Earnings Release, or any detailed financial or governance report. It is also not a regulatory certification or officer attestation. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and patient access programs, which do not fit other specific categories.
2024-10-27 English
Notice under S708A 1 page 200.5KB
Share Issue/Capital Change Classification · 100% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, indicating the issuance of new shares by Percheron Therapeutics Limited. It details the number of shares issued, the issue price, and compliance with relevant sections of the Act. This is a formal announcement related to a share issue, specifically an institutional placement. The document is short (1579 characters) and serves as a regulatory notice about the share issuance rather than a full financial report or detailed capital update. According to the filing definitions, announcements regarding new share issues or capital changes fall under the category 'Share Issue/Capital Change' (Code: SHA).
2024-10-24 English
Application for quotation of securities - PER 5 pages 16.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from Percheron Therapeutics Limited regarding the application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references a previous Appendix 3B announcement related to the securities issuance. The document is an official notice related to the listing or quotation of securities rather than a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, as it concerns the quotation of newly issued shares following a placement. The document length is 4551 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2024-10-23 English
Update - Proposed issue of securities - PER 5 pages 17.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed securities placement by Percheron Therapeutics Limited. It includes specifics such as the number of securities to be issued, issue price, issue date, fees to brokers, and the purpose of the funds raised. The document is an update to a previous announcement, changing the issue date. The content focuses on the capital raising activity and the issuance of new shares, which aligns with announcements related to capital structure changes or fundraising. There is no financial performance data, management discussion, or regulatory certification present. The document is not a full financial report or earnings release but a formal announcement of a securities issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (6655 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2024-10-22 English
Percheron to launch Share Purchase Plan 3 pages 116.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Percheron Therapeutics Limited dated 23 October 2024. It announces a Share Purchase Plan (SPP) for existing shareholders, detailing the terms, pricing, key dates, and conditions of the capital raising. The content focuses on fundraising activities, share issuance, and capital structure changes. There are no financial statements, quarterly or annual results, or management discussion of financial performance. The document is not a report but an announcement of a capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6503 characters) and detailed content support this classification with high confidence.
2024-10-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.